Quanterix makes ultra-sensitive protein detection instruments, consumables, and reagents for life sciences research and clinical diagnostics. The company's core platform, Simoa (Single Molecule Array), detects protein biomarkers in blood at concentrations far below what conventional immunoassay technologies can measure — a capability particularly relevant in neurology, where critical Alzheimer's biomarkers like p-Tau 217 and NfL exist at extremely low concentrations. Quanterix's instrument lineup includes the HD-X and SR-X platforms. In July 2025, Quanterix acquired Akoya Biosciences, adding a Spatial Biology business that maps protein expression across intact tissue samples at single-cell resolution, primarily used in oncology tumor microenvironment research. Quanterix follows a razor-and-blade model: instrument placements drive recurring consumable (assay kits and reagents) revenue, which accounts for roughly 55% of revenue on a pro forma basis. The company also runs an Accelerator Laboratory that performs contract testing for pharma and biotech customers, and operates Lucent Diagnostics, an early-stage clinical testing business offering blood-based Alzheimer's diagnostic tests to physicians. Quanterix's growth strategy centers on expanding its assay menu to increase consumable pull-through, growing into oncology and immunology adjacencies through its next-generation Simoa ONE platform, and building a diagnostics franchise around Alzheimer's disease — a market being unlocked by recent FDA approvals of disease-modifying Alzheimer's therapies that require patient screening before treatment.